Overview

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Collaborator:

Bayer

Treatments:

Oxaliplatin
Vatalanib